8-K: Carmell Corporation to Acquire Elevai Skincare in Strategic Asset Purchase

Carmell Corporation has entered into an agreement to acquire the assets of Elevai Skincare, a move aimed at expanding its presence in the bio-aesthetics market.

Summary

• Carmell Corporation will acquire substantially all assets of Elevai Skincare, including its skincare and haircare business.
• The purchase price includes $1,075,463 in Carmell common stock, with $100,000 held back for 12 months to cover indemnification obligations.
• Carmell will also assume certain liabilities and pay $56,525 in cash after selling specific inventory.
• Additional earnout payments include 5% of net sales from Elevai's existing products over five years and a $500,000 milestone payment if hair and scalp products reach $500,000 in net revenue within 24 months.
• The acquired assets include a product portfolio with $2.5 million in trailing twelve-month revenue, a commercial team, $1.0 million in inventory, and $0.03 million in accounts receivable.
• The deal is expected to close by January 17, 2025, subject to customary closing conditions.

Sentiment

Score: 8

Explanation: The document conveys a positive outlook on the acquisition, highlighting the strategic benefits and potential for growth. The deal structure is reasonable, and the risks are clearly outlined. The sentiment is optimistic but tempered by the inherent uncertainties of any acquisition.

Positives

• The acquisition will integrate stem cell derived exosome technology into Carmell's platform.
• Carmell will acquire a product portfolio with a trailing twelve-month revenue of approximately $2.5 million.
• The deal includes a commercial and product development team, enhancing Carmell's capabilities.
• The acquisition includes approximately $1.0 million in finished and work-in-process inventory.
• The acquisition includes approximately $0.03 million in accounts receivable.

Negatives

• Carmell is assuming certain contractual liabilities and trade payables of Elevai.
• The deal includes earnout payments that are contingent on future performance.
• The closing of the acquisition is subject to customary conditions, which could delay or prevent the deal from closing.

Risks

• The acquisition may not be completed in a timely manner or at all.
• There are risks related to the ability to realize the anticipated benefits of the acquisition.
• The acquisition could divert management's attention from ongoing business.
• There is a risk of unknown liabilities arising after the acquisition.
• The company may be adversely affected by economic, business, and competitive factors.

Future Outlook

Carmell expects to integrate Elevai's business and realize the anticipated benefits of the acquisition, including expanding its product offerings and market presence. The company also plans to launch and commercialize new products.

Management Comments

• Rajiv Shukla, Chairman of Carmell, stated that the acquisition will integrate stem cell derived exosome technology into the Carmell platform.
• Rajiv Shukla, Chairman of Carmell, stated that the acquisition will further cement Carmell's status as the home of the best bio-aesthetic skincare science.

Industry Context

This acquisition reflects a trend in the bio-aesthetics industry where companies are seeking to expand their product portfolios and technological capabilities through strategic mergers and acquisitions. The integration of exosome technology is a significant move, as it represents a cutting-edge approach to skincare and haircare.

Comparison to Industry Standards

• The acquisition of a company with $2.5 million in trailing twelve-month revenue is a significant move for Carmell, indicating a desire for rapid growth.
• The use of stock as part of the purchase consideration is common in acquisitions of this nature, allowing the seller to participate in the potential upside of the combined entity.
• The earnout structure is also a common feature in acquisitions, aligning the interests of the buyer and seller and incentivizing the seller to ensure the continued success of the acquired business.
• The acquisition of a company with a focus on physician-dispensed products aligns with the trend of companies seeking to expand their reach into professional channels.

Stakeholder Impact

• Shareholders of Carmell may see a positive impact from the acquisition, with potential for increased revenue and market share.
• Employees of Elevai will become part of Carmell, potentially leading to new opportunities.
• Customers of Elevai will now be served by Carmell, with the potential for new product offerings.
• Suppliers of Elevai will now be working with Carmell.

Next Steps

• Carmell will work to close the acquisition by January 17, 2025.
• Carmell will integrate Elevai's business into its existing operations.
• Carmell will work to register the resale of the shares issued to the seller.
• Carmell will work to achieve the earnout targets.

Key Dates

Keywords

acquisition, skincare, haircare, bio-aesthetics, exosome technology, asset purchase, Carmell Corporation, Elevai Skincare, PMGC Holdings